Advertisement

Early-Stage Breast Cancer Radiotherapy

  • Kamuran Arslan Ibis
  • Makbule Tambas
  • Seden Kucucuk
Chapter

Abstract

Radiotherapy is part of breast cancer treatment. The addition of radiotherapy to breast-conserving surgery decreases the risk of local recurrence by half in insitu disease. In invasive disease, postmastectomy radiotherapy (PMRT) in patients with 4 or more lymph nodes with metastatic involvement is the standart of care. A recent meta-analysis provided more evidence for PMRT benefit in patients with 1–3 involved nodes. After lumpectomy, whole-breast radiotherapy is still considered the standard of care. A meta-analysis showed a statistically significant increase in in-breast control and a decrease in breast cancer-specific deaths. In addition, boost radiotherapy to the tumor bed after breast-conserving surgery was shown to decrease local failure from 10.2% to 6.2%; the largest benefit was observed in patients ≤40 years of age (local failure decreased from 23.9% to 13%). The results of accelerated partial-breast irradiation (APBI) in patients with low local recurrence risk are controversial. Two large randomized APBI trials showed higher in-breast recurrences in patients treated with APBI than in those treated with whole-breast radiotherapy. Hypofractionation is also an appropriate therapeutic option for most patients with early breast cancer with comparable long-term toxicity profiles. A disease-free survival benefit of regional lymphatic irradiation has been demonstrated in patients with high-risk features with no axillary nodal involvement.

Keywords

Breast conservation Post-mastectomy adjuvant radiotherapy (PMRT) Lymphatic radiotherapy Hypofractionation Accelerated radiotherapy 

References

  1. 1.
    Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247–52.CrossRefGoogle Scholar
  2. 2.
    Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer. 2015;15:890.CrossRefGoogle Scholar
  3. 3.
    EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–7.CrossRefGoogle Scholar
  4. 4.
    Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441–52.CrossRefGoogle Scholar
  5. 5.
    Vargas C, Kestin L, Go N, Krauss D, Chen P, Goldstein N, et al. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys. 2005;63(5):1514–21.CrossRefGoogle Scholar
  6. 6.
    A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I or II breast cancer. NCT00103181. https://clinicaltrials.gov/ct2/show/NCT00103181.
  7. 7.
    Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74(4):987–01.CrossRefGoogle Scholar
  8. 8.
  9. 9.
    Keisch M, Arthur D, Patel R, Rivard M, Vicini F. American brachytherapy society breast brachytherapy task group. http://www.americanbrachytherapy.org/recources/abs_breast_brachytherapy_taskgroup.pdf.
  10. 10.
    Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(32):5319–24.CrossRefGoogle Scholar
  11. 11.
    McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709–15.CrossRefGoogle Scholar
  12. 12.
    Smith BD. When is good enough really good enough? Defining the role of radiation in low-risk ductal carcinoma in situ. J Clin Oncol. 2015;33(7):686–91.CrossRefGoogle Scholar
  13. 13.
    Julien JP, Bijker N, Fentiman IS, Peterse JL, Dellodonne V, Rouanat P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355(9203):528–33.CrossRefGoogle Scholar
  14. 14.
    Houghton J, George WD, Cuzick J, Duggan C, Fentim IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–02.CrossRefGoogle Scholar
  15. 15.
    Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28(4):400–18.CrossRefGoogle Scholar
  16. 16.
    Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol. 2016;6(5):287–95.CrossRefGoogle Scholar
  17. 17.
    National Comprehensive Cancer Network. Breast cancer guidelines. http://nccn.org/professionals/physicians_gls/PDF/breast.pdf. Accessed April 27.
  18. 18.
    Nilsson C, Valachis A. The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiother Oncol. 2015;114(1):50–5.CrossRefGoogle Scholar
  19. 19.
    Moran MS, Zhao Y, Ma S, Kirova YM, Fourquet A, Chen PY, et al. Radiation boost for ductal carcinoma in situ after whole-breast radiation therapy (WBRT) improves local control: analysis from 10 pooled academic institutions. Int J Radiat Oncol Biol Phys. 2016;96(2):144.CrossRefGoogle Scholar
  20. 20.
    Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ. Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44(5):989–90.CrossRefGoogle Scholar
  21. 21.
    Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–55.CrossRefGoogle Scholar
  22. 22.
    Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–8.CrossRefGoogle Scholar
  23. 23.
    Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337(14):956–62.CrossRefGoogle Scholar
  24. 24.
    McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRefGoogle Scholar
  25. 25.
    Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–16.CrossRefGoogle Scholar
  26. 26.
    Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006;24(24):3927–32.CrossRefGoogle Scholar
  27. 27.
  28. 28.
    Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. Ann Surg Oncol. 2017;24(1):38–51.CrossRefGoogle Scholar
  29. 29.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefGoogle Scholar
  30. 30.
    van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143–50.CrossRefGoogle Scholar
  31. 31.
    Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi P, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001;12(7):997–1003.CrossRefGoogle Scholar
  32. 32.
    Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1):6–11.CrossRefGoogle Scholar
  33. 33.
    Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRefGoogle Scholar
  34. 34.
    Valdaya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376(9735):91–102.CrossRefGoogle Scholar
  35. 35.
    Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14(13):1269–77.CrossRefGoogle Scholar
  36. 36.
    Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387(10015):229–38.CrossRefGoogle Scholar
  37. 37.
    Smith GL, Xu Y, Buchholz TA, Smith BD, Giordano SH, Haffty BG, et al. Brachytherapy for accelerated partial-breast irradiation: a rapidly emerging technology in breast cancer care. J Clin Oncol. 2011;29(2):157–65.CrossRefGoogle Scholar
  38. 38.
    Olivotto IA, Whelan TJ, Parpia S, Kim DH, Berrang T, Truong PT, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 2013;31(32):4038–45.CrossRefGoogle Scholar
  39. 39.
    Julian TB, Costantino JP, Vicini FA, White JR, Cecchini RS, Winter KA, et al. A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, 1, or 2 breast cancer: NSABP B-30/RTOG 0413. Cancer Res. 2012;71(24 Suppl.):Abstract nr OT2-06-02.Google Scholar
  40. 40.
    Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, Bissett D, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–73.CrossRefGoogle Scholar
  41. 41.
    Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7.CrossRefGoogle Scholar
  42. 42.
    Romestaing P, Lehingue Y, Carrie C, Couquard R, Montbarbon X, Ardiet JM, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997;15(3):963–8.CrossRefGoogle Scholar
  43. 43.
    Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345(19):1378–87.CrossRefGoogle Scholar
  44. 44.
    Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.CrossRefGoogle Scholar
  45. 45.
    Poortmans P, Bartelink H, Horiot JC, Struikmans H, Van den Bogaert W, Fourquet A, et al. The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ randomised trial. Radiother Oncol. 2004;72(1):25–33.CrossRefGoogle Scholar
  46. 46.
    Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56(5):979–90.CrossRefGoogle Scholar
  47. 47.
    Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma OP, Mittra I. Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer. 1996;74(5):820–4.CrossRefGoogle Scholar
  48. 48.
    Faverly DR, Hendriks JH, Holland R. Breast carcinomas of limited extent: frequency, radiologic-pathologic characteristics, and surgical margin requirements. Cancer. 2001;91(4):647–59.CrossRefGoogle Scholar
  49. 49.
    Frazier TG, Wong RW, Rose D. Implications of accurate pathologic margins in the treatment of primary breast cancer. Arch Surg. 1989;124(1):37–8.CrossRefGoogle Scholar
  50. 50.
    Rosen PP, Fracchia AA, Urban JA, Schottenfeld D, Robbins GF. “Residual” mammary carcinoma following simulated partial mastectomy. Cancer. 1975;35(3):739–47.CrossRefGoogle Scholar
  51. 51.
    Khan AJ, Arthur DW, Dale RG, Haffty BG, Vicini FA. Ultra-short courses of adjuvant breast radiotherapy: promised land or primrose path? Int J Radiat Oncol Biol Phys. 2012;82(2):499–501.CrossRefGoogle Scholar
  52. 52.
    Khan AJ, Arthur DW, Vicini FA. On the road to intraoperative radiotherapy: more ‘proceed with caution’ signs. Oncology (Williston Park). 2013;27(2):113–4.Google Scholar
  53. 53.
    Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75(1):9–17.CrossRefGoogle Scholar
  54. 54.
    Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.CrossRefGoogle Scholar
  55. 55.
    Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–41.CrossRefGoogle Scholar
  56. 56.
    Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–107.CrossRefGoogle Scholar
  57. 57.
    Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P, Bloomfield D, et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100(1):93–100.CrossRefGoogle Scholar
  58. 58.
    Hickey BE, James ML, Lehman M, Hider PN, Jeffery M, Francis DP, et al. Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev. 2016;7:CD003860.PubMedGoogle Scholar
  59. 59.
    Zhou ZR, Mei X, Chen XX, Yang ZZ, Hou J, Zhang L, et al. Systematic review and meta-analysis comparing hypofractionated with conventional fraction radiotherapy in treatment of early breast cancer. Surg Oncol. 2015;24(3):200–11.CrossRefGoogle Scholar
  60. 60.
    Smith BD, Bentzen SM, Correa CR, Hahn CA, Handenberg PH, Ibbott GS, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81(1):59–68.CrossRefGoogle Scholar
  61. 61.
    Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.CrossRefGoogle Scholar
  62. 62.
    Motwani SB, Strom EA, McNeese MD, Buchholz TA. Breast cancer. In: Brady LW, Heliman PH, Molls M, editors. Technical basis of radiation therapy. 4th ed. Berlin: Springer; 2014. p. 485–510.Google Scholar
  63. 63.
    Galper S, Recht A, Silver B, Manola J, Gelman R, Schnitt SJ, et al. Factors associated with regional nodal failure in patients with early stage breast cancer with 0-3 positive axillary nodes following tangential irradiation alone. Int J Radiat Oncol Biol Phys. 1999;45(5):1157–66.CrossRefGoogle Scholar
  64. 64.
    Reddy SG, Kiel KD. Supraclavicular nodal failure in patients with one to three positive axillary lymph nodes treated with breast conserving surgery and breast irradiation, without supraclavicular node radiation. Breast J. 2007;13(1):12–8.CrossRefGoogle Scholar
  65. 65.
    Yates L, Kirby A, Crichton S, Gillett C, Cane P, Fentiman I, et al. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes. Int J Radiat Oncol Biol Phys. 2012;82(5):2093–103.CrossRefGoogle Scholar
  66. 66.
    Strom EA, Woodward WA, Katz A, Buchholz TA, Perkins GH, Jhingran A, et al. Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(5):1508–13.CrossRefGoogle Scholar
  67. 67.
    Truong PT, Jones SO, Kader HA, Wai ES, Speers CH, Alexander AS, et al. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73(2):357–64.CrossRefGoogle Scholar
  68. 68.
    Veronesi U, Amone P, Veronesi P, Galimberti V, Luini A, Rotmensz N, et al. The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. Ann Oncol. 2008;19(9):1553–60.CrossRefGoogle Scholar
  69. 69.
    Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA, et al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014;32(32):3600–6.CrossRefGoogle Scholar
  71. 71.
    Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305.CrossRefGoogle Scholar
  72. 72.
    Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansl RE. Radiotherapy or surgery of axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicenter, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.CrossRefGoogle Scholar
  73. 73.
    Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–27.CrossRefGoogle Scholar
  74. 74.
    Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86(5):860–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kamuran Arslan Ibis
    • 1
  • Makbule Tambas
    • 2
  • Seden Kucucuk
    • 1
  1. 1.Istanbul Medical Faculty, Department of Radiation Oncology, Istanbul University, Institute of OncologyIstanbulTurkey
  2. 2.Department of Radiation OncologyUniversity of Health Sciences, Okmeydanı Training and Research HospitalIstanbulTurkey

Personalised recommendations